Krystal Biotech, Inc. KRYS revenue by segment, product and geography
Krystal Biotech, Inc.'s fiscal year ending 2025-12-31 carries a reported breakdown by business segments.
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$161M100.0%+145.3% yoy
Members sum to the consolidated $161M for this period.
- United States$87.5M75.2%-0.8% yoy
- Europe$20.7M17.8%no prior
- Japan$8.19M7.0%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.